D. Kerstein

发表

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.

Edward S. Kim, H. Groen, E. Smit, 2017 .

Effect of severe renal impairment on the pharmacokinetics of brigatinib

K. Venkatakrishnan, T. Marbury, N. Narasimhan, 2021, Investigational New Drugs.

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer

W. Reichmann, K. Reckamp, S. Krotneva, 2018, Current medical research and opinion.

LBA4EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON–SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES

A. Shaw, S. Gettinger, R. Salgia, 2015 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

J. Hodgson, J. Fletcher, J. Pritchard, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

K. Venkatakrishnan, P. Diderichsen, Pingkuan Zhang, 2020, CPT: pharmacometrics & systems pharmacology.

CASE REPORT Postoperative Use of the NormaTec Pneumatic Compression Device in Vascular Anomalies

S. Talbot, J. Upton, D. Kerstein, 2012, Eplasty.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

C. Gridelli, S. Gettinger, M. Ahn, 2018, The New England journal of medicine.

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

K. Venkatakrishnan, D. Dorer, D. Sonnichsen, 2018, Clinical pharmacology in drug development.

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

K. Venkatakrishnan, N. Narasimhan, E. Offman, 2020, Clinical Pharmacokinetics.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

T. Clackson, A. Shaw, S. Gettinger, 2016, The Lancet. Oncology.

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer.

K. Venkatakrishnan, D. Camidge, N. Narasimhan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).

R. Speck, C. Langer, W. Lenderking, 2019, Future oncology.

Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study

W. Lenderking, Pingkuan Zhang, D. Kerstein, 2019, Journal of medical economics.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2015 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.

J. Supko, D. Jonker, W. Edenfield, 2014 .

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

Edward S. Kim, Dohoung Kim, S. Gettinger, 2017 .

1344PBrigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial

A. Shaw, S. Gettinger, R. Camidge, 2017 .

56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results

A. Shaw, S. Gettinger, R. Salgia, 2016 .

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials

P. Jänne, J. Neal, D. Costa, 2017 .

ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC)

S. Gettinger, S. Peters, D. Camidge, 2016 .

Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

J. Fletcher, G. Demetri, M. Heinrich, 2015 .

Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

S. Gettinger, M. Ahn, D. Camidge, 2018 .

Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.

A. Shaw, S. Gettinger, R. Salgia, 2016 .

Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)‐positive (ALK+) non‐small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330

A. Shaw, S. Gettinger, R. Salgia, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

C. Gridelli, D. Camidge, M. Tiseo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

P. Jänne, J. Neal, Gregory Riely, 2018, Journal of Thoracic Oncology.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

S. Gettinger, S. Ou, M. Ahn, 2017 .

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

D. Tu, J. Zalcberg, J. Simes, 2014 .

A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.

H. Hirte, G. Batist, J. Supko, 2013 .

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .